MA31422B1 - Composition pharmaceutique a liberation prolongee constituee de microparticules - Google Patents

Composition pharmaceutique a liberation prolongee constituee de microparticules

Info

Publication number
MA31422B1
MA31422B1 MA32391A MA32391A MA31422B1 MA 31422 B1 MA31422 B1 MA 31422B1 MA 32391 A MA32391 A MA 32391A MA 32391 A MA32391 A MA 32391A MA 31422 B1 MA31422 B1 MA 31422B1
Authority
MA
Morocco
Prior art keywords
microparticles
pharmaceutical composition
micrometers
release pharmaceutical
prolonged release
Prior art date
Application number
MA32391A
Other languages
English (en)
Inventor
Bertrand Ducrey
Patrick Garrouste
Catherine Curdy
Marie-Anne Bardet
Herve Porchet
Eija Lundstrom
Frederic Heimgartner
Original Assignee
Debio Rech Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40032512&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA31422(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Debio Rech Pharma Sa filed Critical Debio Rech Pharma Sa
Publication of MA31422B1 publication Critical patent/MA31422B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'INVENTION CONCERNE UNE COMPOSITION PHARMACEUTIQUE FAITE DE MICROPARTICULES POUR LA LIBÉRATION LENTE D'UNE SUBSTANCE ACTIVE AU MOINS PENDANT UNE PÉRIODE COUVRANT LES 6 MOIS APRÈS L'INJECTION DE LADITE COMPOSITION, LADITE COMPOSITION COMPRENANT UN GROUPE DE MICROPARTICULES FAITES D'UN COPOLYMÈRE DU TYPE PLGA QUI INCORPORENT UNE SUBSTANCE ACTIVE SOUS LA FORME D'UN SEL DE PEPTIDE INSOLUBLE DANS L'EAU; LEDIT COPOLYMÈRE COMPRENANT DE PLUS AU MOINS 75 % D'ACIDE LACTIQUE ET UNE VISCOSITÉ INHÉRENTE ENTRE 0,1 ET 0,9 DL/G, TELLE QUE MESURÉE DANS LE CHLOROFORME À 25°C ET À UNE CONCENTRATION EN POLYMÈRE DE 0,5/DL; LESDITES MICROPARTICULES AYANT DE PLUS UNE DISTRIBUTION DE DIMENSION DÉFINIE COMME SUIT : - D (V, 0,1 ) SE TROUVE ENTRE 10 ET 30 MICROMÈTRES, - D (V, 0,5) SE TROUVE ENTRE 30 ET 70 MICROMÈTRES, - D(V, 0,9) SE TROUVE ENTRE 50 ET 110 MICROMÈTRES.
MA32391A 2007-06-06 2009-12-01 Composition pharmaceutique a liberation prolongee constituee de microparticules MA31422B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07109767 2007-06-06
IB2007054372 2007-10-27
PCT/IB2008/052241 WO2008149320A2 (fr) 2007-06-06 2008-06-06 Composition pharmaceutique à libération lente, faite de microparticules

Publications (1)

Publication Number Publication Date
MA31422B1 true MA31422B1 (fr) 2010-06-01

Family

ID=40032512

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32391A MA31422B1 (fr) 2007-06-06 2009-12-01 Composition pharmaceutique a liberation prolongee constituee de microparticules

Country Status (32)

Country Link
US (4) US10166181B2 (fr)
EP (3) EP3431077A1 (fr)
JP (1) JP5419169B2 (fr)
KR (1) KR101631475B1 (fr)
CN (1) CN101677959B (fr)
AP (1) AP3000A (fr)
AU (1) AU2008259411B2 (fr)
BR (1) BRPI0812250B8 (fr)
CA (1) CA2688478C (fr)
CO (1) CO6251234A2 (fr)
CY (2) CY1118434T1 (fr)
DK (2) DK2500014T4 (fr)
EA (1) EA019284B1 (fr)
ES (2) ES2694401T5 (fr)
FI (1) FI2500014T4 (fr)
HR (2) HRP20181854T4 (fr)
HU (2) HUE031550T2 (fr)
IL (1) IL202501A (fr)
LT (2) LT2164467T (fr)
MA (1) MA31422B1 (fr)
ME (1) ME00959B (fr)
MX (1) MX2009012856A (fr)
MY (1) MY150450A (fr)
NZ (1) NZ582423A (fr)
PL (2) PL2164467T3 (fr)
PT (2) PT2164467T (fr)
RS (2) RS58248B1 (fr)
SI (2) SI2500014T2 (fr)
TN (1) TN2009000476A1 (fr)
UA (1) UA99830C2 (fr)
WO (1) WO2008149320A2 (fr)
ZA (1) ZA200907940B (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5419169B2 (ja) 2007-06-06 2014-02-19 デビオファーム リサーチ アンド マニュファクチャリング ソシエテ アノニム 微小粒子で構成される徐放性医薬組成物
PT105270B (pt) 2010-08-26 2012-05-31 Domino Ind Ceramicas S A Camada de sílica com libertação lenta de fragrância, telha cerâmica e respectivo processo de produção
CN105267153B (zh) * 2015-11-27 2018-05-11 上海苏豪逸明制药有限公司 一种曲普瑞林缓释微粒及其制备方法
CN105797134B (zh) * 2016-03-29 2019-06-14 浙江圣兆药物科技股份有限公司 一种难溶亮丙瑞林缓释制剂
EP3535297B1 (fr) 2016-11-02 2022-08-10 Debiopharm International, S.A. Procédés d'amélioration d'une thérapie immunoconjuguée anti-cd37
KR102402639B1 (ko) 2017-11-24 2022-05-26 삼성전자주식회사 전자 장치 및 그의 통신 방법
CN111000798B (zh) * 2019-12-26 2021-11-23 四川恒博生物科技有限公司 一种采用原位凝胶技术的犬用非手术去势注射液
IT202000017191A1 (it) 2020-07-15 2022-01-15 Xbrane Biopharma Ab Procedimento senza acqua per preparare una composizione farmaceutica per un rilascio più prolungato e controllato di triptorelina o di un suo sale
AR133300A1 (es) 2023-07-20 2025-09-17 Ferring Bv Micropartículas cargadas con fármaco de liberación prolongada
TW202529795A (zh) * 2023-11-08 2025-08-01 瑞士商戴比歐醫藥國際公司 新穎組成物
CN121401211A (zh) * 2024-02-29 2026-01-27 珠海市华海康医药科技有限责任公司 一种双羟萘酸盐药物缓释微球及其制备方法
CN121818889A (zh) 2024-10-08 2026-04-10 费灵有限公司 曲普瑞林组合物及其用途

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3678308D1 (de) 1985-02-07 1991-05-02 Takeda Chemical Industries Ltd Verfahren zur herstellung von mikrokapseln.
US4897268A (en) * 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
GB2209937B (en) 1987-09-21 1991-07-03 Depiopharm S A Water insoluble polypeptides
US5225205A (en) * 1989-07-28 1993-07-06 Debiopharm S.A. Pharmaceutical composition in the form of microparticles
CH679207A5 (fr) * 1989-07-28 1992-01-15 Debiopharm Sa
MY107937A (en) 1990-02-13 1996-06-29 Takeda Chemical Industries Ltd Prolonged release microcapsules.
CH683149A5 (fr) * 1991-07-22 1994-01-31 Debio Rech Pharma Sa Procédé pour la préparation de microsphères en matériau polymère biodégradable.
FR2693905B1 (fr) * 1992-07-27 1994-09-02 Rhone Merieux Procédé de préparation de microsphères pour la libération prolongée de l'hormone LHRH et ses analogues, microsphères et formulations obtenues.
JP3277342B2 (ja) 1992-09-02 2002-04-22 武田薬品工業株式会社 徐放性マイクロカプセルの製造法
ATE223702T1 (de) * 1993-10-22 2002-09-15 Genentech Inc Verfahren und zusammensetzungen zur mikrokapselung von adjuvantien
US5945128A (en) * 1996-09-04 1999-08-31 Romano Deghenghi Process to manufacture implants containing bioactive peptides
MY118835A (en) 1997-04-18 2005-01-31 Ipsen Pharma Biotech Sustained release compositions and the process for their preparation
AU1384199A (en) * 1997-11-07 1999-05-31 Chiron Corporation Method for producing igf-1 sustained-release formulations
TW200800298A (en) * 2000-01-27 2008-01-01 Zentaris Ag Compressed microparticles for dry injection
US20040170665A1 (en) 2000-06-02 2004-09-02 Allergan, Inc. Intravitreal botulinum toxin implant
CA2463358C (fr) 2001-10-10 2012-03-13 Pierre Fabre Medicament Microspheres biodegradables a liberation prolongee et leur procede de preparation
MXPA05011299A (es) * 2003-04-30 2006-01-24 Debiopharm Sa Metodos y composiciones utilizando la hormona liberadora de la hormona gonadotropina.
KR100466637B1 (ko) * 2003-06-26 2005-01-13 주식회사 펩트론 서방성 미립구의 혼합 제형을 연속한 단일 공정으로제조하는 방법
FR2865938B1 (fr) * 2004-02-05 2006-06-02 Sod Conseils Rech Applic Formulation retard solide comprenant de l'acetate de triptoreline
ES2755032T3 (es) 2005-12-22 2020-04-21 Novartis Ag Formulación de liberación sostenida que comprende octreótido y dos o más polímeros de poliláctido-co-glicólido
JP5419169B2 (ja) 2007-06-06 2014-02-19 デビオファーム リサーチ アンド マニュファクチャリング ソシエテ アノニム 微小粒子で構成される徐放性医薬組成物

Also Published As

Publication number Publication date
AU2008259411B2 (en) 2013-10-17
ES2694401T3 (es) 2018-12-20
RS55591B1 (sr) 2017-06-30
IL202501A (en) 2015-11-30
EP2500014A2 (fr) 2012-09-19
US20230082575A1 (en) 2023-03-16
LT2164467T (lt) 2017-01-25
HUE040391T2 (hu) 2019-03-28
PL2500014T5 (pl) 2025-05-05
KR101631475B1 (ko) 2016-06-20
US20190192423A1 (en) 2019-06-27
HK1141737A1 (en) 2010-11-19
US20250205148A1 (en) 2025-06-26
WO2008149320A2 (fr) 2008-12-11
US20110052717A1 (en) 2011-03-03
HRP20181854T1 (hr) 2019-02-08
SI2164467T1 (sl) 2017-05-31
CY1118434T1 (el) 2017-06-28
JP5419169B2 (ja) 2014-02-19
LT2500014T (lt) 2019-01-25
CO6251234A2 (es) 2011-02-21
CN101677959A (zh) 2010-03-24
ES2694401T5 (es) 2025-05-16
PL2500014T3 (pl) 2019-04-30
ME00959B (fr) 2012-06-20
MX2009012856A (es) 2009-12-15
MY150450A (en) 2014-01-30
EP2500014B2 (fr) 2025-02-19
EP2500014A3 (fr) 2012-11-07
CY1120891T1 (el) 2019-12-11
AP3000A (en) 2014-10-31
AP2009005088A0 (en) 2009-12-31
PT2164467T (pt) 2017-01-13
UA99830C2 (uk) 2012-10-10
DK2500014T3 (en) 2018-12-03
WO2008149320A3 (fr) 2009-02-05
DK2164467T3 (en) 2017-01-30
IL202501A0 (en) 2010-06-30
NZ582423A (en) 2011-10-28
BRPI0812250B8 (pt) 2021-05-25
RS58248B1 (sr) 2019-03-29
ZA200907940B (en) 2010-08-25
HUE031550T2 (en) 2017-07-28
CN101677959B (zh) 2014-02-26
EP2500014B1 (fr) 2018-08-08
CA2688478A1 (fr) 2008-12-11
EP3431077A1 (fr) 2019-01-23
HRP20181854T4 (hr) 2025-05-09
EP2164467B1 (fr) 2016-12-14
EA019284B1 (ru) 2014-02-28
EA200971132A1 (ru) 2010-04-30
EP2164467A2 (fr) 2010-03-24
SI2500014T1 (sl) 2019-02-28
AU2008259411A1 (en) 2008-12-11
KR20100023950A (ko) 2010-03-04
BRPI0812250B1 (pt) 2020-03-03
US10166181B2 (en) 2019-01-01
PL2164467T3 (pl) 2017-07-31
CA2688478C (fr) 2015-10-27
PT2500014T (pt) 2018-11-21
FI2500014T4 (fi) 2025-04-08
JP2010529106A (ja) 2010-08-26
DK2500014T4 (da) 2025-04-14
HRP20161785T1 (hr) 2017-03-10
ES2611020T3 (es) 2017-05-04
SI2500014T2 (sl) 2025-05-30
TN2009000476A1 (en) 2011-03-31
BRPI0812250A2 (pt) 2014-12-23

Similar Documents

Publication Publication Date Title
MA31422B1 (fr) Composition pharmaceutique a liberation prolongee constituee de microparticules
US12060397B2 (en) Soluble lipidated ligand agents for treating eye inflammation
Bhati et al. A detailed review on oral mucosal drug delivery system
MA27285A1 (fr) COMBINAISON D'AZELASTINE ET DE STEROiDES
TNSN98229A1 (fr) Formulation pharmaceutique orale a liberation prolongee
BRPI0015567B8 (pt) composto, composição farmacêutica, forma de unidade de dosagem, uso da composição farmacêutica e método para preparar uma composição farmacêutica
BR9808933A (pt) Composição sob forma de microcápsulas ou de implantes, processo de preparação de uma substância hidrossolúvel, substância ativa, acetato de triptorelina, acetato de lanreotìdeo, ou acetato de octreotìdeo, e rna de filamento duplo
MX350380B (es) Formas de dosificacion solida de liberacion modificada en el orden de cero.
MA26859A1 (fr) Forme posologique de medicament commandée par un hydrogel.
DE60138468D1 (de) Cyanophenoxy-carbonsäuren und zusammensetzungen für die freisetzung aktiver substanzen
CY1107711T1 (el) Υπογλωσσια χορηγηση φαρμακευτικης συνθεσης ως αγωγη εναντι οξεων διαταραχων
EP1790340A3 (fr) Chimotherapie combinée
CA2219475A1 (fr) Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation
WO2001082895A3 (fr) Formulation et comprimes de liberation soutenue de guaifenesine
BRPI0317682B1 (pt) Composição farmacêutica de liberação modificada na forma de uma cápsula
MA34296B1 (fr) Composition retard injectable antipsychotique
NO20000284D0 (no) Tanninsyre-polymerblandinger for kontrollert frigivelse av farmasoeytiske midler, saerlig i munnhulen
MA31006B1 (fr) Composition a liberation prolongee et procede de production correspondant
DE60210552D1 (de) Prozess zur Herstellung einer festen pharmazeutischen Zubereitung welche einen schwerlöslichen Wirkstoff enthält
WO2018018010A1 (fr) Mutants de fgf et leurs utilisations
DE60042972D1 (de) Trimetazidine enthaltendes Arzneimittel mit verzögerter Wirkstoffabgabe und Verfahren zur Herstellung
WO2012109267A2 (fr) Nouveaux peptides et leurs procédés d'utilisation
BR0009472A (pt) Antagonistas de lhrh com propriedades desolubilidade aperfeiçoadas
CN101495150B (zh) 药理活性物质的吸收性被改善的药物组合物
WO2004006854A3 (fr) Procede d'identification d'agents biologiquement actifs